Menstruation Clinical Trials

A listing of Menstruation medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 86 clinical trials
A DOUBLE BLIND RANDOMIZED VEHICLE CONTROLLED CROSSOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOPICAL NALOXONE HYDROCHLORIDE LOTION 0.5% FOR THE RELIEF OF PRURITUS IN PATIENTS WITH THE MYCOSIS FUNGOIDES (MF) FORM OF CUTANEOUS T-CELL LYMPHOMA (CTCL

The crossover treatment design entails an initial randomized assignment to either Naloxone Lotion or the Vehicle Lotion for a two-week period, and after a suitable washout period, an assignment to the alternative treatment for a second two-week period. Study participation involves four periods: a) Screening Period, b) Treatment Period 1, …

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase III multi-center double-blind randomized withdrawal study of LCI699 following a 24 week single-arm open-label dose titration and treatment period to evaluate the safety and efficacy of LCI699 for the treatment of patients with Cushings disease (PRIME)

LC1699 is taken in pill form twice a day. Once eligibility has been confirmed, the study has four periods plus an optional extension period.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Prospective Randomized Double-Blind Placebo-Controlled Crossover Study to Evaluate the Clinical Utility of the Vascular Health Profile Diagnostics Assay (VHP) in Assessment of Response to Administration of a HMG-CoA reductase inhibitor (statin) as Primary Prevention in Patients with Asymptomatic Atherosclerosis

The two treatment periods will be separated by a four-week washout period. During the first period one of the sequence of subjects will receive drug and the other will receive placebo.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study to Evaluate the Effects of Annovera and Tampon Co-Usage on the Pharmacokinetics of Segesterone Acetate and Ethinyl Estradiol

Normal 0 false false false EN-US X-NONE X-NONE This study involves research about Annovera, an FDA-approved contraceptive vaginal system. The Annovera vaginal system is a ring made of a silicone rubber, which is inserted into your vagina. Annovera contains 2 hormones. One is a progestin called segesterone acetate (SA) and …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Randomized Controlled Trial of Home Therapy with Caffeine Citrate in Moderately Preterm Infants with Apnea of Prematurity

The primary outcome of the study will be the number of days of hospitalization from randomization to discharge up to 48 weeks post-menstrual age (PMA), with censoring at time of transfer or death. The eligibility criteria for the study are inborn and outborn infants of 29 0/7 to 33 6/7 …

  • 0 views
  • 19 Feb, 2024
  • 1 location
A multicentre multinational randomised parallel-group placebo-controlled (double blind) and active-controlled (open) trial to compare the efficacy and safety of once weekly dosing of NNC0195-0092 with once weekly dosing of placebo and daily Norditropin FlexPro in adults with growth hormone deficiency for 35 weeks with a 53-week extension period (PRIME)

The trial will compare the efficacy and safety of once weekly dosing of NNC0195-0092 with once weekly dosing of placebo and daily dosing of Norditropin® in adult subjects with growth hormone deficiency.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase 2 Randomized Placebo-Controlled Study of Safety and Efficacy Following Repeat-Dose Administration of Evinacumab (anti-ANGPTL3) in Patients with Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

A phase 2, randomized, placebo-controlled study designed to evaluate the efficacy and safety of repeated doses of evinacumab in adult patients with severe hypertriglyceridemia. The study consists of screening period (up to 37 days), a baseline/single-blind placebo run in period, a 12-week double-blind treatment period, a single-blind 12 week treatment …

  • 0 views
  • 19 Feb, 2024
  • 1 location
AN EXPLORATORY OPEN-LABEL PROOF-OF-CONCEPT PHASE 2A STUDY OF MAVACAMTEN (MYK-461) IN PARTICIPANTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF) AND CHRONIC ELEVATION OF CARDIAC TROPONIN I AND/OR NT-PROBNP

This is a multicenter, exploratory, open-label study to explore the efficacy and/or pharmacodynamic effect, PK, safety, and tolerability of mavacamten in approximately 35 ambulatory participants with symptomatic HFpEF and elevated cTnI and/or elevated NT-proBNP as defined in inclusion/exclusion criteria. The study will include an up to 7-week screening period (with …

  • 0 views
  • 19 Feb, 2024
  • 1 location
North American Registry for Care and Research in MS - NARCRMS

NARCRMS is a national database that collects patient and physician-based information on MS and will bring together information and data collected in multiple registries and databases across the U.S. and Canada. We expect that data collected consistently over long periods of time, when carefully studied, will 1) produce new clues …

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase 2 Multi-center Randomized Double-Blind Placebo-Controlled Dose Range Finding Study to Evaluate the Safety Hemodynamic Effects and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects who have Diabetic Foot Ulcer with Peripheral Arterial Disease

The Screening/Run-In/Pre-Treatment Period will be at least 2 weeks. After the Pre- Treatment Period, subjects will be randomized to a treatment arm and will receive investigational product (IP) PDA-002 cells or placebo.

  • 0 views
  • 19 Feb, 2024
  • 1 location